| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 6,520.0 | 6,057.0 |
| Gross profit | 4,248.0 | 3,852.0 |
| Profit before tax | 997.0 | 1,029.0 |
| Net income | 753.0 | 859.0 |
| EPS (diluted, $ a share) | $1.96 | $2.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -12.3% |
|---|---|
| Revenue, year on year | +7.6% |
| Gross margin | 65.2% |
| Operating margin | 15.9% |
10-Q filed with the SEC, NYSE: SYK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Stryker Corp: key numbers
- Share price
- $310.72Close, Nov 16
- Market cap
- $118B
- Shares outstanding
- 380.69MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Stryker Corp
All →Stryker Insider Ronda E. Stryker Sells $179M of Stock
Ronda E. Stryker sold 550,000 shares of Stryker Corp at $323.19 to $327.69 a share (average $325.32) in 6 transactions, worth $179M in total on Nov 6, 2026. Shares held after the trade: 1,701,375 (-0.6%).
- Value
- $179M
- Shares
- 550,000
- Average price
- $325.32
- Holding change
- -0.6%
- Trade date
- Nov 6, 2026
Stryker Leadership Change
Stryker Corporation has increased its board size from 11 to 12 and elected James E. Davis as a new independent director, effective January 1, 2027. Mr. Davis currently serves as the Chairman, CEO, and President of Quest Diagnostics and brings extensive experience from GE Healthcare and McKinsey & Company. He will receive compensation consistent with the company's existing non-employee director pay structure.
- Counterparty
- James E. Davis
Stryker Financial Results
Stryker reported Q3 2026 net sales of $6.5 billion, representing 7.7% organic growth, though management noted performance fell slightly short of internal expectations. The company also announced a $3.0 billion increase to its share repurchase program and updated its full-year 2026 guidance.
- Term
- Q3 2026
“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter. While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.”
Kevin A. Lobo, Chair and CEO
Stryker Leadership Change
Stryker announced a planned leadership succession where Kevin Lobo will resign as CEO on December 31, 2026, and transition to Executive Chair of the Board. Spencer Stiles, the current President and COO, has been appointed to succeed Lobo as CEO and will join the Board of Directors effective January 1, 2027.